Your patients are declining between visits. Now you can see it.
You know it happens. A Parkinson's patient whose gait was stable three months ago. A cognitive decline patient whose family says something changed but can't explain what. Between your visits, there is no objective signal. No data. Just silence until the next appointment.
GIA®, powered by digitalhumanOS™, analyzes 2,500+ speech biomarkers from a single patient conversation to surface cognitive and neurological decline before your next scheduled visit. Parkinson's disease AUC 0.97. Cognitive decline AUC 0.890. Peer-reviewed across 19 published studies. Results write directly to the EHR.
Key Facts
- Parkinson’s AUC
- 0.97
- Biomarkers
- 2,500+
- Evidence
- See research bibliography
- Review Time
- < 2 min
GIA® gives you eyes in the room when you are not there.
This content is intended for informational purposes and does not constitute medical advice. Citing research does not mean this page or the product has been independently peer reviewed.
90 days of continuous speech biomarker data on your patients between visits. No capital expenditure. No integration project. If the signal is not real, you walk away.
One conversation. Multiple neurological signals.
GIA® screens for 46 conditions total across cognitive, neurological, and behavioral domains. View all conditions.
What happens between your visits stays invisible.
Decline Between Visits
Neurological patients deteriorate in the weeks and months between appointments. By the time you see them again, the window for early intervention has narrowed or closed entirely.
No Objective Data Between Encounters
You rely on patient self-report and caregiver observation — both subjective, both incomplete. There is no continuous objective signal tracking cognitive or motor function between your visits.
Documentation Burden During Visits
Structured intake and documentation consume the minutes you need for clinical judgment. The visit becomes an administrative event instead of a diagnostic one.
Referral Blindness
When you refer a patient to post-acute or long-term care, you lose visibility. The longitudinal record fractures. Deterioration happens in silence.
Peer-reviewed. Not promised.
GIA® Administers ADL and IADL Assessment Instruments
For neurologists managing patients with Parkinson's disease, multiple sclerosis, and cognitive decline, functional staging requires objective ADL and IADL assessment alongside cognitive screening. GIA® administers validated functional assessment instruments during the patient interaction and writes structured results to the EHR.
- Barthel Index — basic ADL assessment for daily function
- Katz Index of Independence — independence in six functions
- Lawton IADL Scale — higher-order functional activities
- Functional Independence Measure (FIM) — functional ability across domains
- All results structured into medical notes and written back to the EHR
- Clinician reviews and approves all results
ADL and IADL assessments are administered separately from GIA®'s 46-condition biomarker screening. Both capabilities complete within a single patient interaction.
Continuous monitoring that travels with the patient.
GIA® conducts speech biomarker screenings wherever the patient is — at home, in a skilled nursing facility, in assisted living. Results write back to the EHR in real time. You see objective signals between visits without adding a single minute to your schedule. The longitudinal record follows the patient across every care setting, not just your office.
Structured intake that gives you back your visit.
Before your patient walks in, GIA® has already captured a structured cognitive and functional screening. You review it in under two minutes. The visit becomes what it should be — your clinical judgment applied to objective data, not spent on intake paperwork.
Deterioration flagged before the next appointment.
GIA® does not wait for the next scheduled visit to surface a problem. When speech biomarkers indicate cognitive or motor decline, the system flags it for your review. You intervene when intervention still matters — not weeks later when the patient is already in crisis.
No commitment. No IT project. Just data.
GIA® arrives on Samsung Health Grade Galaxy devices, pre-configured and ready. Your patients speak with GIA® between visits. Results write to your EHR. You review objective speech biomarker data alongside your clinical assessment and decide whether continuous monitoring changes your practice.
90 days. No capital expenditure. No integration project. No disruption to your existing workflow. If the data does not speak for itself, you walk away.
Start the 90-Day Outcome ProofClinical and technical questions.
The Operator's Guide to Multimodal Clinical AI
EHR integration, staffing impact, reimbursement codes, deployment timelines, and the 5-layer governance framework — in one guide.
They Are Declining Between Visits.
Now you have the data to prove it and the time to act on it.
90 days. No capital expenditure. No integration project. No disruption to your existing practice. If the data does not speak for itself, you walk away.